当前位置:首页 > 关于我们 > 创投导师 > 林勇

林勇 | LIN YONG


林勇大头照.jpg

林勇
北京福伟斯生物科技有限公司总经理。
毕业于中国药科大学;
专注中韩医药&医疗器械项目交易和投资20余年;
曾任韩国SK集团中国医药事业部门代表;
曾任韩国知名上市制药企业中国法人总经理多年;
驻中韩国制药企业协会会员,与韩国大部分头部制药企业维持业务联系;
成功引入韩国多家企业优秀的新药和新医疗器械产品实现本地化;
成功引入韩国多个新药项目,引入签约金额(首付款+里程碑)累计超过1亿美元;
成功帮助华东医药等多家国内知名制药企业产品授权至韩国,累计授权签约金额超过5000万美元;
SK Biopharm等多家韩国领先企业中国战略顾问。

LIN YONG
General manager of Beijing Forewest Biotech Ltd.
China Strategy Consultant of many Korean leading companies including SK Biopharm.
Graduated from China Pharmaceutical University;
Devoted to investment of medicine and medical devices projects between Korean and China;
He used to be the representative of Chinese Medical Division of SK Group in Korean, and the general manager in China of a famous Korean public traded company.
He is a member of Korean Pharmaceutical Company Association in China, in contact with most Korean pharmaceutical companies.
He succeeded in introducing plenty of novel drugs and medical devices of Korean companies into China, with contract amount added up to over $ 100 million.
He also helped products of Chinese pharmaceutical companies such as Huadong Medicine Co. Ltd licensed into Korean, with contract amount added up to over $ 50 million.

0.176452s